An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

National Agricultural Library
U.S. Department of Agriculture
  1. Home
  2. Human Nutrition and Food Safety
  3. Research Publications (Food Safety)

Research Publications (Food Safety)

This page tracks research articles published in national and international peer-reviewed journals. Recent articles are available ahead of print and searchable by Journal, Article Title, and Category. Research publications are tracked across six categories: Bacterial Pathogens, Chemical Contaminants, Natural Toxins, Parasites, Produce Safety, and Viruses. Articles produced by USDA Grant Funding Agencies (requires login) and FDA Grant Funding Agencies (requires login) are also tracked in Scopus.

Displaying 1 - 25 of 60

  1. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  2. The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID‐19 vaccines

    • Allergy

    • Allergy, Accepted Article.

      • Viruses
      • COVID-19

  3. COVID‐19 vaccines tolerated in patients with paclitaxel and docetaxel allergy

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  4. Childhood BCG vaccination seems to selectively protect adult males from COVID‐19 infection

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  5. Mast cell activation is associated with post‐acute COVID‐19 syndrome

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  6. Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  7. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID‐19 vaccines in Europe

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 72-82, January 2022.

      • Viruses
      • COVID-19

  8. COVID‐19 vaccines—The way forward

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 15-16, January 2022.

      • Viruses
      • COVID-19

  9. COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 304-307, January 2022.

      • Viruses
      • COVID-19

  10. Antiviral response in vernal keratoconjunctivitis may be protective against COVID‐19

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 298-300, January 2022.

      • Viruses
      • COVID-19

  11. Adding the variable of environmental complexity into the COVID‐19 pandemic equation

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 331-333, January 2022.

      • Viruses
      • COVID-19

  12. Successful administration of second dose of BNT162b2 COVID‐19 vaccine in two patients with potential anaphylaxis to first dose

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 337-338, January 2022.

      • Viruses
      • COVID-19

  13. Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 173-185, January 2022.

      • Viruses
      • COVID-19

  14. Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 118-129, January 2022.

      • Viruses
      • COVID-19

  15. Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 258-270, January 2022.

      • Viruses
      • COVID-19

  16. Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 282-295, January 2022.

      • Viruses
      • COVID-19

  17. One Health: EAACI Position Paper on coronaviruses at the human‐animal interface, with a specific focus on comparative and zoonotic aspects of SARS‐CoV‐2

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 55-71, January 2022.

      • Viruses
      • COVID-19

  18. Adherence to subcutaneous immunotherapy with aeroallergens in real‐life practice during the COVID‐19 pandemic

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 197-206, January 2022.

      • Viruses
      • COVID-19

  19. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 143-149, January 2022.

      • Viruses
      • COVID-19

  20. Comparative proteomics of common allergenic tree pollens of birch, alder and hazel

    • Allergy

    • In addition to known allergens, other proteins in pollen can aid the development of an immune response in allergic individuals. The contribution of the “unknown” protein allergens is apparent in phylogenetically related species where, despite of high homology of the lead allergens, the degree of allergenic potential can vary greatly.

      • Chemical contaminants
      • Heavy Metals

  21. Recent Patents in Allergy/Immunology: New pyrazinones for the diagnosis of allergies to aminocephalosporins

    • Allergy

    • Cephalosporins are, after penicillins, the most important β‐lactam inductors of immediate allergic reactions.

  22. The Global Burden of Illness of Peanut Allergy: A Comprehensive Literature Review

    • Allergy

    • Peanut allergy (PA) currently affects approximately 2% of the general population of Western nations and may be increasing in prevalence. Patients with PA and their families/caregivers bear a considerable burden of self‐management to avoid accidental peanut exposure and to administer emergency medication (adrenaline) if needed. Compared with other food allergies, PA is associated with higher rates of accidental exposure, severe reactions, and potentially fatal anaphylaxis.

  23. Drug‐specific T‐cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat

    • Allergy

    • Background Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer’s disease. Elevations in hepatic enzymes were detected in a number of in trial patients, which resulted in termination of the drug development programme. Immunohistochemical characterization of liver tissue from an index case of atabecestat‐mediated liver injury revealed an infiltration of T‐lymphocytes in areas of hepatocellular damage.

  24. Spotlight on microRNAs in allergy and asthma

    • Allergy

    • In past ten years, microRNAs (miRNAs) have gained scientific attention due to their importance in the pathophysiology of allergic diseases and theirpotential as biomarkersin liquid biopsies. They act as master post‐transcriptional regulators that control most cellular processes.

      • Chemical contaminants
      • Heavy Metals

  25. Systemic allergic reactions induced by labile plant‐food allergens: seeking potential co‐factors. a multicenter study

    • Allergy

    • Background Heat‐and pepsin‐sensitive plant food allergens (PR‐10 and profilin) sometimes cause systemic reaction. Objective To detect the risk factors for systemic reactions induced by labile food allergens. Methods A retrospective multicenter study was performed on patients with a documented history of systemic allergic reaction to labile plant food allergens and on age‐matched controls with a history of oral allergy syndrome (OAS) induced by the same foods.